Weekly Investment Analysts’ Ratings Updates for Glaukos (GKOS)

Glaukos (NYSE: GKOS) recently received a number of ratings updates from brokerages and research firms:

• 6/21/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/17/2026 – Glaukos had its price target raised by Needham & Company LLC from $136.00 to $150.00. They now have a “buy” rating on the stock.
• 6/13/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/11/2026 – Glaukos had its price target raised by Citigroup Inc. from $140.00 to $162.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $162.00 price target on the stock.
• 5/30/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/26/2026 – Glaukos had its “outperform” rating reaffirmed by William Blair.
• 5/21/2026 – Glaukos had its price target raised by BTIG Research from $141.00 to $162.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/30/2026 – Glaukos was given a new $170.00 price target by Stifel Nicolaus.
• 4/30/2026 – Glaukos had its price target raised by Citigroup Inc. from $135.00 to $140.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by JPMorgan Chase & Co. from $120.00 to $140.00. They now have an “overweight” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by Wells Fargo & Company from $135.00 to $138.00. They now have an “overweight” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by BTIG Research from $131.00 to $141.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by Needham & Company LLC from $127.00 to $136.00. They now have a “buy” rating on the stock.

Insider Activity at Glaukos

In related news, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the sale, the director directly owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 19,573 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the transaction, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at approximately $10,538,563.26. The trade was a 21.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 41,273 shares of company stock worth $5,832,003 over the last three months. 5.90% of the stock is currently owned by insiders.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.